Navigation Links
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Date:1/16/2008

LONDON, Jan. 16 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.

"We are entirely satisfied with these results," said Dr. Yuval Cohen, President of Morria. "They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market." Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi- functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known, but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

Contact:

Meghan Feeks

+1-212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily ... Datascope Corp. for a potential electrical test failure code.     ... PART NUMBER ... IABP CS300 IABP ... ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... and Drug Administration (FDA) has notified the Company that the ... Zhejiang, China manufacturing facility has been closed ... of the Warning Letter related to our ... the progress we have made in our ongoing quality and ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
Breaking Medicine Technology:
(Date:6/26/2017)... CA (PRWEB) , ... June 26, 2017 , ... Torrance ... Smile aesthetics can be one of the most noticeable aspects of a person’s appearance. ... While not everyone is born with beautiful, balanced teeth, everyone can have the smile ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced ... hiring of Richard Robinson as chief operating officer (COO). In this role, Robinson ... proven track record of simplifying business processes and developing growth strategies to increase ...
(Date:6/26/2017)... Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... 10,000 qualified mental health professionals in every state across the country to join its ... easy and rewarding way for therapists to reach a substantially greater number of people ...
(Date:6/26/2017)... ... ... New patients with missing teeth in Fitchburg, WI, can now ... Cotey is a trusted dentist who has placed many dental implants and enjoys teaching ... teeth in Fitchburg, WI, are encouraged to find out if they are candidates for ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United ... replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the American ... need to be reconciled in committee, or the House will have to take up ...
Breaking Medicine News(10 mins):